Undifferentiated carcinoma of the corpus uteri

Summary

Undifferentiated carcinoma of the corpus uteri (MONDO:0016267) is a cancer. A subtype of uterine carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	undifferentiated carcinoma of the corpus uteri
Mondo ID	MONDO:0016267
Orphanet	213721
ICD-10-CM	C54.9
UMLS	C4707822
MedGen	1638762
GARD	0020480
Anatomy (UBERON)	UBERON:0009853
Is cancer (heuristic)	yes

Also known as: body of uterus undifferentiated carcinoma

Disease family

This is a subtype of uterine carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma › undifferentiated carcinoma of the corpus uteri

Related subtypes (8): endometrial carcinoma, uterus carcinoma in situ, cervical carcinoma, endometrial serous adenocarcinoma, squamous cell carcinoma of the corpus uteri, papillary carcinoma of the corpus uteri, adenoid cystic carcinoma of the corpus uteri, transitional cell carcinoma of the corpus uteri

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.